The landscape for transgender rights and healthcare is experiencing notable, if divergent, changes. In England, NHS England has signalled a review of GPs’ collaboration with certain private providers that offer gender-affirming care, raising questions about where patients should safely obtain hormone treatments. At the same time, Nepal celebrated a significant political first when Bhumika Shrestha was confirmed as a proportional-representation MP on 16 March, a symbolic moment for visibility and legislative advocacy in the region.
These two stories together illustrate how policy, clinical governance and political inclusion intersect. The English review focuses on the formal mechanism known as a shared care agreement — an arrangement where a specialist or private clinic supports a GP to prescribe treatments — and whether that mechanism should be used where private services are not commissioned by the NHS. Meanwhile, Shrestha’s appointment highlights long-standing efforts to convert legal recognition into everyday rights and protections for transgender and non-binary people.
NHS England’s review: scope and immediate effects
According to recent NHS statements, health officials are assessing the risks associated with working with what they describe as unregulated providers of hormone therapy, and have already advised GPs to refuse shared care agreements for patients under 18 with certain private clinics. Named examples include private services such as GenderGP and Anne Trans Healthcare limited. Although the current guidance is explicitly aimed at minors, NHS England says it will consider whether a similar approach should apply to adults as part of a broader clinical commissioning policy related to exogenous hormones in 2026/26. This review follows related decisions, such as pausing new referrals for 16–17-year-olds for MAF (masculinising and feminising) hormones, while continuing treatment for existing patients pending individual clinical review.
What officials say and the review process
Officials have framed the action as a patient safety response, emphasising caution where services operate outside NHS commissioning. NHS England has commissioned evidence reviews — including one on the effectiveness of HRT for trans adults — as part of an Equality and Health Inequalities Impact Assessment that implements recommendations made by Dr Hilary Cass in 2026. The service has signalled that the forthcoming evidence will inform whether existing prescribing pathways remain appropriate.
Responses from advocacy groups and private providers
Community organisations and some private clinics have pushed back on the review, noting that long waits in NHS gender services drive people to seek care elsewhere. Campaigners argue that an informed-consent model could reduce delays and limit unsafe sourcing of medications. TransActual’s policy lead criticised the review for not addressing capacity problems in NHS services, while providers such as Gender Plus, rated Outstanding by regulators, said the NHS interpretation diverges from international expert consensus on gender-affirming care.
Practical impacts on patients and prescribers
General practitioners have in recent years sometimes discontinued prescriptions for trans patients citing expertise or safeguarding concerns, even as they continue to prescribe hormonal treatments for other indications such as menopause or precocious puberty. The NHS guidance advising against reliance on medications from unregulated sources aims to protect safety, but advocates warn it could further restrict access without parallel increases in NHS capacity and clearer, evidence-based pathways.
Nepal’s milestone: representation and expectations
Across continents, Nepal’s elevation of Bhumika Shrestha to parliament on 16 March marks a historic political gain. Shrestha identifies as third gender, a legal recognition first affirmed in Nepal’s courts in 2007. Her appointment followed confirmation by the Election Commission after the Rastriya Swatantra Party secured seats under proportional representation. For many activists and community members, this is not merely symbolic: it creates an opportunity to translate constitutional promises into concrete laws, policies and protections.
Community celebrations at the Kathmandu offices of the Blue Diamond Society reflected both pride and a sense of work ahead. Supporters gifted flowers and scarves in recognition of the moment, while Shrestha herself spoke of responsibility to push for the legal and policy changes that would make constitutional provisions meaningful for everyday life in Nepal.
Putting the developments in context
Taken together, the English policy review and the Nepalese parliamentary milestone underline two complementary facets of trans rights: access to safe clinical care and the importance of political voice. Where governance and capacity problems constrain clinical pathways, people may seek alternatives outside regulated systems — a dynamic that prompts safety concerns and stricter oversight. Conversely, increased representation like Shrestha’s can help direct attention and resources toward reforming laws and services so that inclusion is more than a legal formality.
Ultimately, both stories point to ongoing debates about how best to combine clinical evidence, patient autonomy and institutional responsibility. As NHS England proceeds with evidence reviews and as Nepal’s newly appointed lawmaker begins her parliamentary role, the global conversation about trans healthcare and rights continues to evolve in ways that will affect policy, practice and lived experience.